tiprankstipranks
Trending News
More News >
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Advertisement

Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics

Compare
1,470 Followers

Total Valuation

Ovid Therapeutics has a market cap or net worth of $68.98M. The enterprise value is -$788.97K.
Market Cap$68.98M
Enterprise Value-$788.97K

Share Statistics

Ovid Therapeutics has 71,109,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,109,510
Owned by Insiders5.36%
Owned by Institutions31.35%

Financial Efficiency

Ovid Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -73.40%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-73.40%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee24.61K
Profits Per Employee-1.15M
Employee Count23
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Ovid Therapeutics is ―. Ovid Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.97
Price to FCF
Price to Operating Cash Flow-0.03
PEG Ratio

Income Statement

In the last 12 months, Ovid Therapeutics had revenue of 566.00K and earned -26.43M in profits. Earnings per share was -0.37.
Revenue566.00K
Gross Profit566.00K
Operating Income-61.88M
Pretax Income-26.43M
Net Income-26.43M
EBITDA-57.77M
Earnings Per Share (EPS)-0.37

Cash Flow

In the last 12 months, operating cash flow was -40.07M and capital expenditures -18.00K, giving a free cash flow of -40.06M billion.
Operating Cash Flow-40.07M
Free Cash Flow-40.06M
Free Cash Flow per Share-0.56

Dividends & Yields

Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.09
52-Week Price Change-17.70%
50-Day Moving Average0.47
200-Day Moving Average0.61
Relative Strength Index (RSI)76.86
Average Volume (3m)2.37M

Important Dates

Ovid Therapeutics upcoming earnings date is Nov 12, 2025, TBA (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 12, 2025
Ex-Dividend Date

Financial Position

Ovid Therapeutics as a current ratio of 5.32, with Debt / Equity ratio of 2.48%
Current Ratio5.32
Quick Ratio5.32
Debt to Market Cap0.02
Net Debt to EBITDA0.20
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Ovid Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Ovid Therapeutics EV to EBITDA ratio is -0.95, with an EV/FCF ratio of -0.98.
EV to Sales96.57
EV to EBITDA-0.95
EV to Free Cash Flow-0.98
EV to Operating Cash Flow-0.98

Balance Sheet

Ovid Therapeutics has $38.35M in cash and marketable securities with $1.38M in debt, giving a net cash position of -$36.96M billion.
Cash & Marketable Securities$38.35M
Total Debt$1.38M
Net Cash-$36.96M
Net Cash Per Share-$0.52
Tangible Book Value Per Share$0.96

Margins

Gross margin is 98.51%, with operating margin of -10933.75%, and net profit margin of -4670.14%.
Gross Margin98.51%
Operating Margin-10933.75%
Pretax Margin-4670.14%
Net Profit Margin-4670.14%
EBITDA Margin-10207.07%
EBIT Margin-10315.37%

Analyst Forecast

The average price target for Ovid Therapeutics is $2.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$2.92
Price Target Upside213.98% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast1071.91%
EPS Growth Forecast-27.61%

Scores

Smart Score8
AI Score54
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis